Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start biologics after anti-HBV treatment. We investigated the risk of HBV reactivation according to the timing of biologics initiation after anti-HBV treatment in immune-mediated inflammatory disease (IMID) patients with HBV infection. Methods: We retrospectively evaluated the incidence of HBV reactivation in IMID patients who received biologics between July 2005 and April 2020. The patients were divided into two groups (within 1-week and after 1-week) according to the timing of biologics initiation after anti-HBV treatment. The cumulative probabilities and factors associated with HBV reactivation were evaluated. Results: A total of 60 hepatitis B surface antigen-positive patients with IMID received biologics (within 1-week group, n=23 [38%]; after 1-week group, n=37 [62%]). During a median follow-up of 34 months (interquartile range, 20 to 74 months), three patients (5%) developed HBV reactivation. In univariate analysis, the timing of biologics after anti-HBV treatment was not significantly associated with the risk of HBV reactivation (hazard ratio, 0.657; 95% confidence interval, 0.059 to 7.327; p=0.733). The cumulative probabilities of HBV reactivation did not significantly differ according to the timing of biologics (p=0.731). Conclusions: The risk of HBV reactivation was not significantly associated with the timing of biologics administration after anti-HBV treatment. Thus, biologics may be initiated early in patients with IMID undergoing treatment for HBV.
Abstract
Background/Aims: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start biologics after anti-HBV treatment. We investigated the risk of HBV reactivation according to the timing of biologics initiation after anti-HBV treatment in immune-mediated inflammatory disease (IMID) patients with HBV infection. Methods: We retrospectively evaluated the incidence of HBV reactivation in IMID patients who received biologics between July 2005 and April 2020. The patients were divided into two groups (within 1-week and after 1-week) according to the timing of biologics initiation after anti-HBV treatment. The cumulative probabilities and factors associated with HBV reactivation were evaluated. Results: A total of 60 hepatitis B surface antigen-positive patients with IMID received biologics (within 1-week group, n=23 [38%]; after 1-week group, n=37 [62%]). During a median follow-up of 34 months (interquartile range, 20 to 74 months), three patients (5%) developed HBV reactivation. In univariate analysis, the timing of biologics after anti-HBV treatment was not significantly associated with the risk of HBV reactivation (hazard ratio, 0.657; 95% confidence interval, 0.059 to 7.327; p=0.733). The cumulative probabilities of HBV reactivation did not significantly differ according to the timing of biologics (p=0.731). Conclusions: The risk of HBV reactivation was not significantly associated with the timing of biologics administration after anti-HBV treatment. Thus, biologics may be initiated early in patients with IMID undergoing treatment for HBV.
참고문헌 (32)
- Kuek A, "Immune-mediated inflammatory diseases(IMIDs)and biologic therapy : a medical revolution", Postgrad Med J, 83, pp.251~260 (2007)
- Choon Jin Ooi, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intestinal research, 17(3), pp.285~310 (2019), 대한장연구학회[DOI]
- Tomohiro Fukuda, "Current new challenges in the management of ulcerative colitis", Intestinal research, 17(1), pp.36~44 (2019), 대한장연구학회[DOI]
- Gómez-Reino JJ, "Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk : a multicenter active-surveillance report", Arthritis Rheum, 48, pp.2122~2127 (2003)
- 예병덕, "Improving the quality of care for inflammatory bowel disease", Intestinal research, 17(1), pp.45~53 (2019), 대한장연구학회[DOI]
- Seto WK, "Chronic hepatitis B virus infection", Lancet, 392, pp.2313~2324 (2018)
- Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection : a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)
- Reddy KR, "American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.215~219 (2015)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015update", Hepatol Int, 10, pp.1~98 (2016)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- European Association for the Study of the Liver, "EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Soo-Kyung Park, "Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases", Intestinal research, 18(1), pp.18~33 (2020), 대한장연구학회
- Lau CS, "2018 update of the APLAR recommendations for treatment of rheumatoid arthritis", Int J Rheum Dis, 22, pp.357~375 (2019)
- Gupta S, "Spontaneous reactivation in chronic hepatitis B : patterns and natural history", J Clin Gastroenterol, 12, pp.562~568 (1990)
- Esteve M, "Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients : need for primary prophylaxis", Gut, 53, pp.1363~1365 (2004)
- Loras C, "Impact of surveillance of hepatitis B and hepatitis C in patients with inflammatory bowel disease under anti-TNF therapies : multicenter prospective observational study(REPENTINA 3)", J Crohns Colitis, 8, pp.1529~1538 (2014)
- Pérez-Alvarez R, "Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases", Medicine(Baltimore), 90, pp.359~371 (2011)
- Tamori A, "Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy : evaluation of both HBsAg-positive and HBsAg-negative cohorts", J Gastroenterol, 46, pp.556~564 (2011)
- 이정일, "류마티스질환 환자에서 생물학적 제제 사용 시 B형 간염바이러스의 재활성화: 스크리닝 및 치료", 대한류마티스학회지, 22(5), pp.282~287 (2015), 대한류마티스학회
- 박은정, "Reactivation of Hepatitis B Virus and Its Prevention in Patients with Rheumatic Diseases Receiving Immunosuppressive Therapy", 대한류마티스학회지, 24(5), pp.261~270 (2017), 대한류마티스학회
- Perrillo RP, "American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.221~244 (2015)
- Lee YH, "Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs", Int J Rheum Dis, 16, pp.527~531 (2013)
- Zhang MY, "Systematic review with network meta-analysis : comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation", Oncotarget, 7, pp.30642~30658 (2016)
- Vassilopoulos D, "Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection", Ann Rheum Dis, 69, pp.1352~1355 (2010)
- Ryu HH, "Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents : a retrospective analysis of 49cases", Clin Rheumatol, 31, pp.931~936 (2012)
- Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
- Yu S, "Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy : a meta-analysis", Int J Clin Pharm, 38, pp.1035~1043 (2016)
- Yang C, "Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation", Ann Hepatol, 15, pp.501~511 (2016)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Carroll MB, "Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection", Semin Arthritis Rheum, 38, pp.208~217 (2008)
- Pauly MP, "Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists", Clin Gastroenterol Hepatol, 16, pp.1964~1973 (2018)
- Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies : current concepts, management strategies, and future directions", Gastroenterology, 152, pp.1297~1309 (2017)